Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Asuragen, Exosome Name New CEOs; McComb Joins Bio-Rad Board; More


Asuragen said this week that it has appointed Matthew McManus as CEO and president.

McManus was most recently CEO and president of PrimeraDx, an MDx platform developer recently acquired by Qiagen. Prior to this, he was head of Cleveland Clinic Laboratories and chief operating officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He holds an MD and PhD from the University of Pennsylvania School of Medicine and an MBA from Boston College.

Asuragen also said this week that it has named Darin Leigh as senior vice president of commercial operations and Eric Lindquist as vice president of business development, companion diagnostics.

Prior to joining Asuragen, Leigh was vice president of global commercial operations with Luminex. He also served in strategic marketing and sales roles at Abbott Laboratories. Lindquist has held senior roles in business development, sales, and marketing at HTG, Ventana/Roche, Apocell, Vysis/Abbott, and Veridex.

Exosome Diagnostics has appointed Thomas McLain as CEO. The company also announced that it is relocating its headquarters from New York to Cambridge, Mass.

McLain most recently was CEO of Vermillion, a medical diagnostics firm focusing on women's health. Prior to this, he was CEO of Claro Scientific, a diagnostics company with a novel optics-based platform technology. He has also served as CEO, chairman, and president of Nabi Biopharmaceuticals.

In a statement, Exosome Chairman Kapil Dhingra noted that McLain's "recent experience in the development and commercialization of non-invasive diagnostic tests is especially relevant to the opportunities that lie ahead for us."

McLain replaces James McCullough, who was founding CEO of Exosome.

Bio-Rad Laboratories said recently that it has appointed Joel McComb to its board of directors.

Since mid-2010 McComb has founded three technology companies in the life science and diagnostics markets under the umbrella of Point Break Capital. The technologies focus on RNA expression, cancer profiling, and pathology. McComb previously served as vice president and general manager of Illumina's Life Science business unit, where he was responsible for leading global product development, business strategy, and overall operations. Prior to joining Illumina, McComb held two high-level positions at General Electric, serving as president of GE Healthcare Life Sciences-Discovery Systems and president of GE Healthcare Interventional Medicine. McComb has also served as president and CEO of Innovadyne Technologies, and held a series of executive, product development, business, and sales positions at Beckman Coulter.

Insight Genetics said this week that it has added six employees, growing its expertise in scientific research and development and quality assurance.

Rebecca Smith and Lance Thomas have joined the company as scientists. Smith will support the Insight Genetics R&D team in late-phase projects for transition to clinical use. She was previously a developmental neurobiology postdoctoral fellow at St. Jude Children's Research Hospital. Thomas will lead the design and execution of early phase projects and support the next-generation sequencing division at Insight. He was previously a postdoctoral fellow at Vanderbilt University Medical Center.

Frank McMahon, Sajid Qadri, and Ryan Vincent have joined the company as research associates. McMahon will oversee the expansion of Insight's histopathology division and support biomarker development projects. He previously gained significant research experience in molecular pathology at the Vanderbilt University Medical Center in the Allergy Pulmonary and Critical Care and Translational Pathology departments. Qadri will work on NGS projects, having previously served as a research intern for the company. Vincent will help design and advance projects as part of Insight's R&D team.

Finally, Andrew Dahlhauser has joined the company as a quality assurance associate, responsible for implementing Insight's quality management system processes within Insight and with the company's external clients.

Biocept, an oncology MDx firm specializing in circulating tumor cells and circulating tumor DNA biomarker analysis, has named Amy McNeal as senior director of managed care and reimbursement strategies.

McNeal joins Biocept from GE Healthcare where she was manager of the North American managed care unit. Prior to this, she was executive director of sales and contracting at Pathology, a specialty women's health laboratory. She has also previously led health plan contracting efforts for Quest Diagnostics.